Enwei Pharmaceutical Co., Ltd. (SHE:301331)

Enwei Pharmaceutical Revenue

Enwei Pharmaceutical had revenue of 199.25M CNY in the quarter ending June 30, 2026, a decrease of -21.16%. This brings the company's total for the last twelve months to 826.13M, down -5.39% year-over-year. In the year 2025, Enwei Pharmaceutical had annual revenue of 900.77M with 10.91% growth. That makes Enwei Pharmaceutical the 21,036th largest company in the world by revenue and 3,864th in China.

• Revenue (ttm): 826.13M
• Revenue Growth: -5.39%
• P/S Ratio: 2.72
• Revenue / Employee: 550.39K
• Employees: 1,501
• Market Cap: 2.25B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Manufacturing 896.64M 99.5%
• Others 4.14M 0.5%

By Geography

Chart

• East China 244.11M 27.1%
• Southwest China 151.71M 16.8%
• Southern China 150.78M 16.7%
• Unallocated 104.21M 11.6%
• Central China 92.02M 10.2%
• North China 76.14M 8.5%
• Northeast China 42.66M 4.7%
• Northwestern China 39.13M 4.3%

Fiscal year ended Dec 31, 2025 See the full Enwei Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	900.77M	88.64M	10.91%
Dec 31, 2024	812.13M	26.94M	3.43%
Dec 31, 2023	785.19M	93.62M	13.54%
Jan 1, 2023	691.57M	11.88M	1.75%
Jan 1, 2022	679.70M	45.54M	7.18%

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error